INCSTAR DISCONTINUING FLUORESCENCE POLARIZATION IMMUNOASSAY R&D
This article was originally published in The Gray Sheet
Executive Summary
INCSTAR DISCONTINUING FLUORESCENCE POLARIZATION IMMUNOASSAY R&D, the firm announced at its annual shareholders' meeting May 17. "Much more [research and development] expense was going to be necessary to develop a broad enough menu of tests to differentiate our FPIA system (reagents plus instrument) from other automated diagnostic systems already on the market," President and CEO Orwin Carter explained.